This article has been updated from a previous version that incorrectly stated that 7 percent of Qiagen's revenue came from Genaco. The article should have stated that 7 percent of Qiagen's third quarter revenue came from acquisitions.
 
Qiagen officials said this week that the company would seek US Food and Drug Administration clearance next year to market two PCR-based multiplex panels developed by the recently acquired Genaco Biomedical.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.